cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.8025875.v1
title: Refinement of the Child Amblyopia Treatment Questionnaire (CAT-QoL) using Rasch analysis

description: <i>Aims or Purpose:</i> The Child Amblyopia Treatment Questionnaire (CAT-QoL) was developed using a “bottom-up” methodological approach. Interviews with children with amblyopia identified items (questions) and response levels to be tested in a draft questionnaire consisting of 11 items (sad, feeling on face, hurt, doing schoolwork, cross, how other children treat you, doing things, worried, upset with family, playing with friends, happy). This study describes the refinement of the descriptive system for the CAT-QoL instrument using the application of Rasch analysis. <i>Methods:</i> A multi-centre pilot study was conducted, and data collected from 342 participants. Participants were asked to self-complete the appropriate treatment version of the CAT-QoL questionnaire socio-demographic and clinical data were collected by the clinician using a standardised proforma. A “measure” of child’s health was obtained from the parent by asking how they would rate their child’s health over the previous week. Rasch analysis techniques were applied to refine the questionnaire. Rasch was used to examine response categories and collapse item response levels, identify poorly performing items, and explore local dependency of items. <i>Results:</i> A total of 331 subjects were included in the study sample, however only 315 were accepted into the RUMM program as a number of subjects had missing questions responses on the CAT-QoL. RUMM also excluded a further 41 subjects as these demonstrated extreme responses. Disordered response categories were found for each item, requiring adjacent response levels to be combined. This was applied to all items, and the model fit was re-examined. Two items were found to have poor fit (cross and happy) and were removed from the measure and the model fit was re-examined. No statistically significant differential item functioning (DIF) was found for any item, using person factors of age, sex or general health. Two items showed some dependency (worried and upset with family), and the poorer fitting item was subsequently removed (upset with family). This resulted in a refined CAT-QoL instrument that consists of 8-items, each with three-level response scales. <i>Conclusion:</i> The refined CAT-QoL instrument includes the following items: sad, feeling on face, hurt, doing work at school, how other children treat you, doing things, worried and playing with friends. The CAT-QoL can be Rasch scored, with a range of 0–16 where a greater value indicates a worse quality of life (or greater impact of treatment on the individual). The CAT-QoL may be useful in determining how amblyopia treatment affects children, and offers an alternative to generic patient reported outcome measures.
DOI: 10.6084/m9.figshare.8025590
title: Perinatal Risk Factors for the Retinopathy of Prematurity in Postnatal Growth and Rop Study

description: <b>Objective</b>: To evaluate perinatal risk factors for retinopathy of prematurity (ROP), in a large, broad-risk cohort of premature infants. <b>Study design</b>: Secondary analysis of data from the Postnatal Growth and ROP (G-ROP) Study, a retrospective cohort study of infants undergoing ROP examinations at 29 North American hospitals in 2006–2012. <b>Results</b>: Among 7483 infants, 3224 (43.1%) had any ROP and 931 (12.4%) had severe ROP (Type 1 or 2 ROP). In multivariable logistic regression analysis, significant risk factors for any ROP were lower birth weight (BW, odds ratio (OR) = 5.2, &lt;501 g vs. &gt;1250 g), younger gestational age (GA, OR = 32, &lt;25 vs. &gt;29 weeks), 1-min Apgar score &lt;4 (OR = 1.2), race (OR = 1.6, White vs. Black), outborn (OR = 1.5), and delivery room intubation (OR = 1.3); and for severe ROP were lower BW (OR = 20, &lt;501 g vs. &gt;1250 g), younger GA (OR = 30, &lt;25 vs. &gt;29 weeks), male (OR = 1.5), Hispanic ethnicity (OR = 1.8), race (OR = 1.6, White vs. Black), outborn (OR = 1.6), and delivery room intubation (OR = 1.6). Together, these factors predicted well for any ROP (area under ROC curve (AUC) = 0.87) and severe ROP (AUC = 0.89), but BW and GA were the dominant factors for ROP (AUC = 0.86) and severe ROP (AUC = 0.88). <b>Conclusions</b>: Based on the largest report to date with detailed ROP data from infants meeting current screening guidelines, ROP risk is predominantly determined by the degree of prematurity at birth, with other perinatal factors contributing minimally.
DOI: 10.6084/m9.figshare.8025590.v1
title: Perinatal Risk Factors for the Retinopathy of Prematurity in Postnatal Growth and Rop Study

description: <b>Objective</b>: To evaluate perinatal risk factors for retinopathy of prematurity (ROP), in a large, broad-risk cohort of premature infants. <b>Study design</b>: Secondary analysis of data from the Postnatal Growth and ROP (G-ROP) Study, a retrospective cohort study of infants undergoing ROP examinations at 29 North American hospitals in 2006–2012. <b>Results</b>: Among 7483 infants, 3224 (43.1%) had any ROP and 931 (12.4%) had severe ROP (Type 1 or 2 ROP). In multivariable logistic regression analysis, significant risk factors for any ROP were lower birth weight (BW, odds ratio (OR) = 5.2, &lt;501 g vs. &gt;1250 g), younger gestational age (GA, OR = 32, &lt;25 vs. &gt;29 weeks), 1-min Apgar score &lt;4 (OR = 1.2), race (OR = 1.6, White vs. Black), outborn (OR = 1.5), and delivery room intubation (OR = 1.3); and for severe ROP were lower BW (OR = 20, &lt;501 g vs. &gt;1250 g), younger GA (OR = 30, &lt;25 vs. &gt;29 weeks), male (OR = 1.5), Hispanic ethnicity (OR = 1.8), race (OR = 1.6, White vs. Black), outborn (OR = 1.6), and delivery room intubation (OR = 1.6). Together, these factors predicted well for any ROP (area under ROC curve (AUC) = 0.87) and severe ROP (AUC = 0.89), but BW and GA were the dominant factors for ROP (AUC = 0.86) and severe ROP (AUC = 0.88). <b>Conclusions</b>: Based on the largest report to date with detailed ROP data from infants meeting current screening guidelines, ROP risk is predominantly determined by the degree of prematurity at birth, with other perinatal factors contributing minimally.
DOI: 10.6084/m9.figshare.8025326
title: Supplementary Material for: Characterization of Initial Stages of Diabetic Macular Edema

description: <b><i>Purpose:</i></b> This study is aimed at characterizing the type of retinal edema in the initial stages of retinopathy in type 2 diabetes. <b><i>Methods:</i></b> In this retrospective cross-sectional study, spectral domain optical coherence tomography (OCT) layer by layer analysis of the retina in association with OCT-Leakage, an algorithm to detect sites of low optical reflectivity, were used to examine eyes with minimal, mild, and moderate diabetic retinopathy (DR). <b><i>Results:</i></b> A total of 142 eyes from 142 patients (28% women) aged 52–88 years were imaged. Macular edema, either subclinical (SCME) or central-involved macular edema (CIME), was present in 43% of eyes in group 10–20, 41% of eyes in group 35, and 38% of eyes in group 43–47. The inner nuclear layer (INL) was the layer showing higher and most frequent increases in retinal thickness (79%). The edema was predominantly intracellular in group 10–20 (65%) and extracellular in groups 35 (77%) and 43–47 (69%). <b><i>Conclusions:</i></b> Eyes from diabetic patients in the initial stages of DR with different Early Treatment Diabetic Retinopathy Study gradings show similar prevalence of SCME and CIME, independent of the severity of the retinopathy. Retinal edema is located mainly in the INL and appears to be mostly extracellular except in the earliest stages of diabetic retinal disease where intracellular edema predominates.
DOI: 10.6084/m9.figshare.8025245
title: Supplementary Material for: Does the 5-Aminosalicylate Concentration Correlate with the Efficacy of Oral 5-Aminosalicylate and Predict Response in Patients with Inflammatory Bowel Disease? A Systematic Review

description: <b><i>Background:</i></b> Oral 5-aminosalicylic acid (5-ASA, mesalazine) is the first choice therapeutic agent for treating mild-to-moderate ulcerative colitis (UC). Unfortunately a significant group of patients fail to respond. Therapeutic drug monitoring might help to maintain or induce remission by providing a tool for optimization of 5-ASA therapy. However, plasma and urine concentrations of 5-ASA reflect systemic uptake and are not useful to evaluate therapeutic effect. <b><i>Objectives:</i></b> To explore if mucosal and faecal 5-ASA values correlate with disease activity and/or therapeutic effects in patients with inflammatory bowel disease, especially UC. <b><i>Method:</i></b> We identified studies that analysed 5-ASA in faeces or mucosa of humans using an oral 5-ASA formulation, using PubMed and Embase. <b><i>Results:</i></b> In total, 39 studies (<i>n</i> = 939) were included, 27 on faecal 5-ASA, 9 on mucosal concentrations, and 3 on both faecal and mucosal values. We included 33 cross-sectional studies, 3 randomised clinical trials, 2 longitudinal cohorts and 1 randomized cross-over study. Mucosal 5-ASA concentrations in healthy subjects and patients on equivalent doses of 5-ASA were not found to differ remarkably. In the sub-analysis of mucosal 5-ASA concentrations in patients with active or quiescent UC, a higher concentration was seen during remission. Faecal concentrations were associated with 5-ASA doses but not with disease activity. Differences in faecal or mucosal 5-ASA values could not be ascribed to different 5-ASA formulations. <b><i>Conclusions:</i></b> An increase of the mucosal 5-ASA concentrations was observed during remission in patients with UC. No clear relationship between the faecal 5-ASA excretion and the therapeutic efficacy was identified.
DOI: 10.6084/m9.figshare.8025272
title: My report

description: Introduction<br>introduction <br><br>Methods<br>Super puper Methoduper<br><br>Results<br>Good very good results<br><br>Discussion<br>Discussion no need discussion. There is nothing to discuss.<br><br>
DOI: 10.6084/m9.figshare.8025245.v2
title: Supplementary Material for: Does the 5-Aminosalicylate Concentration Correlate with the Efficacy of Oral 5-Aminosalicylate and Predict Response in Patients with Inflammatory Bowel Disease? A Systematic Review

description: <b><i>Background:</i></b> Oral 5-aminosalicylic acid (5-ASA, mesalazine) is the first choice therapeutic agent for treating mild-to-moderate ulcerative colitis (UC). Unfortunately a significant group of patients fail to respond. Therapeutic drug monitoring might help to maintain or induce remission by providing a tool for optimization of 5-ASA therapy. However, plasma and urine concentrations of 5-ASA reflect systemic uptake and are not useful to evaluate therapeutic effect. <b><i>Objectives:</i></b> To explore if mucosal and faecal 5-ASA values correlate with disease activity and/or therapeutic effects in patients with inflammatory bowel disease, especially UC. <b><i>Method:</i></b> We identified studies that analysed 5-ASA in faeces or mucosa of humans using an oral 5-ASA formulation, using PubMed and Embase. <b><i>Results:</i></b> In total, 39 studies (<i>n</i> = 939) were included, 27 on faecal 5-ASA, 9 on mucosal concentrations, and 3 on both faecal and mucosal values. We included 33 cross-sectional studies, 3 randomised clinical trials, 2 longitudinal cohorts and 1 randomized cross-over study. Mucosal 5-ASA concentrations in healthy subjects and patients on equivalent doses of 5-ASA were not found to differ remarkably. In the sub-analysis of mucosal 5-ASA concentrations in patients with active or quiescent UC, a higher concentration was seen during remission. Faecal concentrations were associated with 5-ASA doses but not with disease activity. Differences in faecal or mucosal 5-ASA values could not be ascribed to different 5-ASA formulations. <b><i>Conclusions:</i></b> An increase of the mucosal 5-ASA concentrations was observed during remission in patients with UC. No clear relationship between the faecal 5-ASA excretion and the therapeutic efficacy was identified.
DOI: 10.6084/m9.figshare.8025173
title: New dicynodonts (Therapsida, Anomodontia) from near the Permo-Triassic boundary of Laos: implications for dicynodont survivorship across the Permo-Triassic mass extinction and the paleobiogeography of Southeast Asian blocks

description: The dicynodonts are an emblematic group of herbivorous therapsids that survived the Permo-Triassic (P-Tr) crisis. Laotian dicynodonts from stratigraphically constrained beds, recently dated using the U-Pb zircon method, yield new insights into terrestrial faunas of Southeast Asia during the latest Permian and earliest Triassic. Summarily described, they were originally attributed to the genus <i>Dicynodon</i>. We provide a new phylogenetic analysis for Laotian dicynodonts, based on three well-preserved skulls, indicating that they belong to two new taxa: <i>Counillonia superoculis</i>, gen. et sp. nov., and <i>Repelinosaurus robustus</i>, gen. et sp. nov. Our phylogenetic analysis of Dicynodontia indicates that (1) <i>Counillonia</i> is closely related to some ‘<i>Dicynodon</i>’-grade taxa and (2) <i>Repelinosaurus</i> is a kannemeyeriiform. The phylogenetic affinities of these new Laotian dicynodonts allow discussion of the survivorship of multiple lineages (Kannemeyeriiformes and ‘<i>Dicynodon</i>’-grade dicynodontoids) across the P-Tr crisis. The Laotian dicynodonts also shed new light on the paleobiogeography of Southeast Asia from the late Paleozoic to the early Mesozoic, particularly the timing of collisions between the Indochina, the South China, and the North China blocks. The presence of dicynodonts in Laos, most likely in the Early Triassic, thus implies that the connection between the Indochina Block and the South China Block occurred no later than the latest Permian or earliest Triassic (i.e., when the dicynodonts provide direct evidence for a connection).
DOI: 10.6084/m9.figshare.8025272.v2
title: My report

description: Introduction<br>introduction <br><br>Methods<br>Super puper Methoduper<br><br>Results<br>Good very good results<br><br>Discussion<br>Discussion no need discussion. There is nothing to discuss.<br><br>
DOI: 10.6084/m9.figshare.8025245.v1
title: Supplementary Material for: Does the 5-Aminosalicylate Concentration Correlate with the Efficacy of Oral 5-Aminosalicylate and Predict Response in Patients with Inflammatory Bowel Disease? A Systematic Review

description: <b><i>Background:</i></b> Oral 5-aminosalicylic acid (5-ASA, mesalazine) is the first choice therapeutic agent for treating mild-to-moderate ulcerative colitis (UC). Unfortunately a significant group of patients fail to respond. Therapeutic drug monitoring might help to maintain or induce remission by providing a tool for optimization of 5-ASA therapy. However, plasma and urine concentrations of 5-ASA reflect systemic uptake and are not useful to evaluate therapeutic effect. <b><i>Objectives:</i></b> To explore if mucosal and faecal 5-ASA values correlate with disease activity and/or therapeutic effects in patients with inflammatory bowel disease, especially UC. <b><i>Method:</i></b> We identified studies that analysed 5-ASA in faeces or mucosa of humans using an oral 5-ASA formulation, using PubMed and Embase. <b><i>Results:</i></b> In total, 39 studies (<i>n</i> = 939) were included, 27 on faecal 5-ASA, 9 on mucosal concentrations, and 3 on both faecal and mucosal values. We included 33 cross-sectional studies, 3 randomised clinical trials, 2 longitudinal cohorts and 1 randomized cross-over study. Mucosal 5-ASA concentrations in healthy subjects and patients on equivalent doses of 5-ASA were not found to differ remarkably. In the sub-analysis of mucosal 5-ASA concentrations in patients with active or quiescent UC, a higher concentration was seen during remission. Faecal concentrations were associated with 5-ASA doses but not with disease activity. Differences in faecal or mucosal 5-ASA values could not be ascribed to different 5-ASA formulations. <b><i>Conclusions:</i></b> An increase of the mucosal 5-ASA concentrations was observed during remission in patients with UC. No clear relationship between the faecal 5-ASA excretion and the therapeutic efficacy was identified.
DOI: 10.6084/m9.figshare.8025173.v1
title: New dicynodonts (Therapsida, Anomodontia) from near the Permo-Triassic boundary of Laos: implications for dicynodont survivorship across the Permo-Triassic mass extinction and the paleobiogeography of Southeast Asian blocks

description: The dicynodonts are an emblematic group of herbivorous therapsids that survived the Permo-Triassic (P-Tr) crisis. Laotian dicynodonts from stratigraphically constrained beds, recently dated using the U-Pb zircon method, yield new insights into terrestrial faunas of Southeast Asia during the latest Permian and earliest Triassic. Summarily described, they were originally attributed to the genus <i>Dicynodon</i>. We provide a new phylogenetic analysis for Laotian dicynodonts, based on three well-preserved skulls, indicating that they belong to two new taxa: <i>Counillonia superoculis</i>, gen. et sp. nov., and <i>Repelinosaurus robustus</i>, gen. et sp. nov. Our phylogenetic analysis of Dicynodontia indicates that (1) <i>Counillonia</i> is closely related to some ‘<i>Dicynodon</i>’-grade taxa and (2) <i>Repelinosaurus</i> is a kannemeyeriiform. The phylogenetic affinities of these new Laotian dicynodonts allow discussion of the survivorship of multiple lineages (Kannemeyeriiformes and ‘<i>Dicynodon</i>’-grade dicynodontoids) across the P-Tr crisis. The Laotian dicynodonts also shed new light on the paleobiogeography of Southeast Asia from the late Paleozoic to the early Mesozoic, particularly the timing of collisions between the Indochina, the South China, and the North China blocks. The presence of dicynodonts in Laos, most likely in the Early Triassic, thus implies that the connection between the Indochina Block and the South China Block occurred no later than the latest Permian or earliest Triassic (i.e., when the dicynodonts provide direct evidence for a connection).
DOI: 10.6084/m9.figshare.8025272.v1
title: My report

description: Introduction<br>introduction erundaction<br><br>Methods<br>Super puper Methoduper<br><br>Results<br>Good very good results<br><br>Discussion<br>Discussion no need discussion. There is nothing to discuss.<br><br>
DOI: 10.6084/m9.figshare.8025053
title: Ипотечный жилой массив

description: vfylgbadhvobpubvhiadsihb
DOI: 10.6084/m9.figshare.8025011
title: Longitudinal impact of the Women’s Health Initiative study on hormone therapy use in Australia

description: <b>Purpose:</b> This study aimed to examine the longitudinal impact of evidence changes on menopausal hormone therapy (MHT) use in Australia. <b>Methods:</b> We analyzed two datasets of subsidized and total MHT use (2000–2016) using segmented regression analysis to explore the impact of the Women’s Health Initiative (WHI) 2002 and 2007 studies. Analyses were stratified by class, route, and strength. Use was measured in defined daily dose/1000 women/day (DDD/1000/day) or packs/1000 women/month (packs/1000/month). <b>Results:</b> The drop in total MHT use after the WHI 2002 was substantial. The biggest decreases in class, route, and strength were estrogens (28.99 DDD/1000/day, 95% confidence interval [CI] 23.97, 34.01), oral (46.07 DDD/1000/day, 95% CI 41.13, 51.01), and medium strength (34.95 packs/1000/month, 95% CI 30.17, 39.73), respectively. However, vaginal use remained stable (−1.83 DDD/1000/day, 95% CI −3.83, 0.17). Profiles of total and subsidized use were similar over time. Utilization levels were relatively unchanged after 2007. Decreased utilization contributed to product discontinuation, with a lag of up to 4 years. Product discontinuation in 2009 further decreased utilization. <b>Discussion and conclusions:</b> MHT use remained low after 2002 despite evidence favoring its use in women younger than 60 years or within 10 years postmenopause. Continued low use could relate to the WHI 2002 media coverage, therapy objectives, key stakeholder uncertainty, health policies, and medicine availability.
DOI: 10.6084/m9.figshare.8025053.v1
title: Ипотечный жилой массив

description: vfylgbadhvobpubvhiadsihb
DOI: 10.6084/m9.figshare.8024981
title: Salt accumulation at inclined slopes. Field and Lab. measurements

description: This is the raw data from field and laboratory measurements in which the salt accumulation along inclined surfaces was measured.
DOI: 10.6084/m9.figshare.8025011.v1
title: Longitudinal impact of the Women’s Health Initiative study on hormone therapy use in Australia

description: <b>Purpose:</b> This study aimed to examine the longitudinal impact of evidence changes on menopausal hormone therapy (MHT) use in Australia. <b>Methods:</b> We analyzed two datasets of subsidized and total MHT use (2000–2016) using segmented regression analysis to explore the impact of the Women’s Health Initiative (WHI) 2002 and 2007 studies. Analyses were stratified by class, route, and strength. Use was measured in defined daily dose/1000 women/day (DDD/1000/day) or packs/1000 women/month (packs/1000/month). <b>Results:</b> The drop in total MHT use after the WHI 2002 was substantial. The biggest decreases in class, route, and strength were estrogens (28.99 DDD/1000/day, 95% confidence interval [CI] 23.97, 34.01), oral (46.07 DDD/1000/day, 95% CI 41.13, 51.01), and medium strength (34.95 packs/1000/month, 95% CI 30.17, 39.73), respectively. However, vaginal use remained stable (−1.83 DDD/1000/day, 95% CI −3.83, 0.17). Profiles of total and subsidized use were similar over time. Utilization levels were relatively unchanged after 2007. Decreased utilization contributed to product discontinuation, with a lag of up to 4 years. Product discontinuation in 2009 further decreased utilization. <b>Discussion and conclusions:</b> MHT use remained low after 2002 despite evidence favoring its use in women younger than 60 years or within 10 years postmenopause. Continued low use could relate to the WHI 2002 media coverage, therapy objectives, key stakeholder uncertainty, health policies, and medicine availability.
DOI: 10.6084/m9.figshare.8024975
title: DAFTAR NILAI STASE KMB.docx

description: nilai stase KMB<br>
DOI: 10.6084/m9.figshare.8024975.v1
title: DAFTAR NILAI STASE KMB.docx

description: nilai stase KMB<br>
DOI: 10.6084/m9.figshare.8024981.v1
title: Salt accumulation data from evaporating slopes in the Lab.

description: This is the raw data from laboratory experiments in which the salt accumulation along inclined surfaces was measured. Measurements done over slopes at inclinations of 5, 30, and 90 degrees. Two repetitions were done for each slope, for fine and coarse texture sands. Water content (WC) was measured and salinity in electric conductivity (EC) units.
DOI: 10.6084/m9.figshare.8024912
title: PIJAT BAYI

description: pendidikan kesehatan merupakan metode yang efektif dalam meningkatkan pengetahuan orang tua dalam hal pijat bayi.Pijat bayi menjadikan tumbuh kembang bayi akan lebih maksimal, bayi akan lebih dekat dengan orangtua karena sentuhan pijat bayi.
DOI: 10.6084/m9.figshare.8024912.v1
title: PIJAT BAYI

description: pendidikan kesehatan merupakan metode yang efektif dalam meningkatkan pengetahuan orang tua dalam hal pijat bayi.Pijat bayi menjadikan tumbuh kembang bayi akan lebih maksimal, bayi akan lebih dekat dengan orangtua karena sentuhan pijat bayi.
DOI: 10.6084/m9.figshare.8024858
title: Softshell turtle genome assemblies scaffolded with Hi-C data

description: This dataset, associated with our prospected publication by Kadota et al., contains softshell turtle genome assemblies based on Hi-C scaffolding. <br><br>See the file "Assembly_ID.xlsx" for details of the combinations of tissue, enzyme, scaffolding program and parameters, and the number of input read pairs. <br><br>Note that the scaffold IDs contained in the files are not systematically given according to their lengths. <br><br>Laboratory for Phyloinformatics, RIKEN BDRhttps://www.bdr.riken.jp/en/research/labs/kuraku-s/<br>